In 2024, Merck’s Keytruda continued to dominate with $29.5 billion in sales, growing 18% over 2023’s $25 billion in sales. Yet the GLP-1 class is nipping at Keytruda’s heels and a patent expiry threatens the oncology stalwart’s reign. Novo Nordisk’s Ozempic surged 38% to $17.5 billion while Eli Lilly’s Mounjaro exploded with 969% growth to…
The post 2024’s blockbusters: Top 25 drugs by sales appeared first on Drug Discovery and Development.
